| 000 | 01888cam a2200229 4500500 | ||
|---|---|---|---|
| 005 | 20260329022141.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aWeber, Benedikt _eauthor |
| 700 | 1 | 0 |
_aRadakovic, Sonja _eauthor |
| 700 | 1 | 0 |
_aTanew, Adrian _eauthor |
| 245 | 0 | 0 | _aApremilast for extensive and treatment-resistant alopecia areata: a retrospective analysis of five patients |
| 260 | _c2020. | ||
| 500 | _a11 | ||
| 520 | _aBackground: Recent experimental data suggest a role for apremilast in the treatment of alopecia areata. Small clinical studies have so far provided contradictory results. Objectives: We retrospectively evaluated the efficacy and safety of apremilast in five cases of extensive and treatment-resistant alopecia areata. Materials and Methods: Apremilast was given at a dose of 30 mg, twice daily, over six months. The efficacy of apremilast treatment was determined by monthly assessment of the affected scalp surface area using SALT scoring. Results: In four out of five patients, no sustained improvement in SALT score was observed within the treatment period. Two of these patients had a slight but only transient improvement after two months of treatment. One patient responded to apremilast treatment with a progressive and marked improvement, as reflected by an 83% reduction in SALT score. Conclusion: Our results are in line with the varying treatment responses in previous studies. Future studies on the efficacy of apremilast treatment in confirmed alopecia areata patient groups are warranted. | ||
| 690 | _aalopecia areata | ||
| 690 | _aapremilast | ||
| 690 | _aphosphodiesterase-4 inhibitor | ||
| 690 | _aSALT score | ||
| 786 | 0 | _nEuropean Journal of Dermatology | 30 | 2 | 2020-03-01 | p. 165-168 | 1167-1122 | |
| 856 | 4 | 1 | _uhttps://stm.cairn.info/revue-european-journal-of-dermatology-2020-2-page-165?lang=en&redirect-ssocas=7080 |
| 999 |
_c1917979 _d1917979 |
||